Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

BACKGROUND: The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts be...

Descripción completa

Detalles Bibliográficos
Autores principales: Irlam-Jones, J J, Eustace, A, Denley, H, Choudhury, A, Harris, A L, Hoskin, P J, West, C M L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997544/
https://www.ncbi.nlm.nih.gov/pubmed/27441495
http://dx.doi.org/10.1038/bjc.2016.218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997544/
https://www.ncbi.nlm.nih.gov/pubmed/27441495
http://dx.doi.org/10.1038/bjc.2016.218

Ejemplares similares